Silver Book Fact

Cardiovascular disease mortality has declined by over 50% since 1950, contributing more than any other factor to the increase of life expectancy during the past few decades.

Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • TAVR improves quality of life in SAS patients
     
  • Death Rates for Coronary Heart Disease, 1950-1998  
  • A calculated approximate benefit-to-cost ratio for antihypertensive therapy is 10:1 for men and 6:1 for women.  
  • Statin treatment soon after an acute heart attack reduces the risk of fatal heart disease or a recurrent heart attack by 24%.  
  • According to the National Institutes of Health, use of the clot-busting drug t-PA saves $4,400 per patient in hospitalization and nursing home costs.